Products
Peginterferon beta-1a is commercially available as a solution for injection in a prefilled syringe (Plegridy). It was approved in many countries in 2015.
Structure and properties
Peginterferon beta-1a is a covalent conjugate of interferon beta-1a (Rebif) and methoxypolyethylene glycol with methylpropionaldehyde as a linker.
Effects
Peginterferon beta-1a (ATC L03AB13) has antiviral, antiproliferative, antitumor, and immunomodulatory properties. It slows disease progression, decreases the frequency of relapses, and reduces their severity.
Indications
For the treatment of relapsing-remitting multiple sclerosis.
Dosage
According to the SmPC. The drug is injected subcutaneously every two weeks. This is in contrast to interferon beta-1a, which must be administered subcutaneously three times per week.
Contraindications
- Hypersensitivity
- Current severe depression and/or suicidal ideation
For complete precautions, see the drug label.
Interactions
Interferons may decrease the activity of CYP450 isozymes, causing appropriate drug-drug interactions.
Adverse effects
The most common possible adverse effects include flu-like illness, fever, headache, muscle and joint pain, chills, weakness, and pain, redness, and itching at the injection site.
